By Benjamin Chiou
Date: Wednesday 28 Oct 2026
(Sharecast News) - GSK reported a 5% increase in third-quarter sales on Wednesday, driven by strong growth in specialty medicines, as the pharmaceutical giant reaffirmed its full-year guidance.
| Velzatinib obtains ODD in Japan for GIST treatment | 19-Nov-2026 | 07:00 | RNS |
| FDA approves Nelkarmi for pretreated ALK+ NSCLC | 18-Nov-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 17-Nov-2026 | 15:30 | RNS |
| Bexsero booster receives positive CHMP opinion | 13-Nov-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 12-Nov-2026 | 15:30 | RNS |
| GSK profit boosted amid planned drug trials | 28-Oct-2026 | Times |
| GSK invests £400m to relocate research headquart... | 28-Jul-2026 | Times |
| GSK to buy US cancer treatment firm Nuvalent for... | 09-Jun-2026 | Guardian |
| GSK signs £45m deal with UCL offshoot for liver ... | 08-Jun-2026 | Times |
| Strong vaccine sales deliver an early boost for ... | 29-Apr-2026 | Times |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,827.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 2,208.00p |
| 52 Week Low | 1,735.50p |
| Volume | 0 |
| Shares Issued | 4,045.44m |
| Market Cap | £73,910m |
| Beta | 0.00 |
| RiskGrade | 129 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 3 |
| Buy | 3 |
| Neutral | 13 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 21 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 12-Nov-26 | 13-Aug-26 |
| Paid | 07-Jan-27 | 08-Oct-26 |
| Amount | 17.00p | 17.00p |
You are here: research